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ABSTRACT 
 
Presently, the administration of therapeutic proteins through non-parenteral routes poses 
a challenge due to stability problems, mainly attributed to pH and high enzymatic content 
present in mucosal surfaces. Therefore, the administration of proteins through mucosal routes 
requires the development of suitable carriers which confer stability and protection against 
harsh environments of the organism and that further facilitate macromolecule permeation. 
Polymeric nanoparticles have been proposed as valuable systems to overcome these 
biological barriers, showing, in some cases, useful properties of controlled release and cellular 
internalization. In this context, there is also a growing tendency towards the use of natural 
polymers such as polysaccharides, because of their unique properties and high 
biocompatibility and biodegradable profile. 
 In this work, fucoidan/chitosan (FUC/CS) nanoparticles were prepared by 
polyelectrolyte complexation. The aim lying in the development of these carriers is the 
expectation that they confer stability and protection to the biomolecules against mucosal 
environments, such as pH and enzymatic contents, providing a non-parenteral route for the 
administration of protein-based drugs. In this study, bovine albumin serum, insulin and 
ovalbumin were used as model proteins. Several FUC/CS mass ratios (4/1 to 1/4) were tested, 
resulting in nanoparticles with different sizes (338-676 nm) and zeta potentials (+41 a -49 
mV). Nanoparticles FUC/CS = 1/4 and 4/1 were proposed for BSA encapsulation and 
variables such as order of polymer addition over each other and the polymeric solution with 
which the protein was mixed at first, were tested for their ability to affect the nanoparticles 
encapsulation efficiency.  Efficiencies as high as 100% were registered (FUC/CS = 4/1) and 
the tested variables were found to have a stronger effect on the formulation FUC/CS = 1/4. 
The small sizes and high negative and positive charges displayed by the developed 
nanoparticles, in addition of their ability to associate macromolecules, were considered to 
hold potential for an application in mucosal delivery. 
 
 
Keywords: Chitosan, Fucoidan, Mucosal routes, Nanoparticles, Proteins  
V 
 
RESUMO 
 
Presentemente, a administração de proteínas terapêuticas por vias não-parentéricas 
representa um desafio, devido aos problemas de estabilidade, principalmente atribuídos ao pH 
e conteúdo enzimáticas em superfícies mucosas. O uso de vias mucosas para a administração 
de proteínas exige assim, o desenvolvimento de transportadores adequados que confiram 
estabilidade e proteção contra ambientes agressivos encontrados no organismo e que ainda 
facilitam a permeação das macromoléculas. As nanopartículas poliméricas surgem então com 
o fim de ultrapassar estas barreiras biológicas, evidenciando ainda, em alguns casos, 
propriedades úteis de libertação controlada e internalização celular. Neste contexto, sugere 
ainda uma tendência crescente para o uso de polímeros naturais, tais como polissacáridos, 
devido às suas características únicas e propriedades de elevada biocompatibilidade e perfil 
biodegradabilidade.  
Neste trabalho, foram preparadas nanopartículas fucoidan/quitosano (FUC/CS) por 
complexação polieletrolítica. Ao desenvolver estes sistemas a expectativa é de que eles 
confiram estabilidade e proteção para as biomoléculas contra ambientes das mucosas, tais 
como o pH e elevados conteúdo enzimáticos, proporcionando uma rota não-parenteral para a 
administração de medicamentos à base de proteínas.Neste estudo, a albumina de soro bovino, 
insulina e ovalbumina foram utilizadas como proteínas modelos. Foram testados vários rácios 
mássicos de FUC/CS (4/1 a 1/4), que resultaram na criação de nanopartículas com diferentes 
tamanhos (338-676 nm) e potenciais zeta (+41 a -49 mV). As FUC/CS= 1/4 e 4/1, foram 
propostas para o encapsulamento da BSA, onde as variáveis tais como a ordem de adição de 
polímeros (protocolo A e B) e a pré-incorporação da proteína, numa das soluções poliméricas, 
foram testadas pela capacidade de manipular a eficiência de encapsulação  (EE) das 
nanopartículas. Eficiências de encapsulação de 100% foram registadas (FUC/CS= 4/1) e a as 
variáveis testadas mostraram ter maior influência nas formulações FUC/CS=1/4. Os pequenos 
tamanhos e as elevadas cargas negativas e positivas das nanopartículas desenvolvidas, foram 
considerados adequados para a aplicação na administração de macromoléculas pela via 
mucosa. 
Palavras-chave: Fucoidan, Nanopartículas, Proteínas, Quitosano, Vias mucosas 
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RESUMO ALARGADO 
 
Das inúmeras doenças que normalmente afetam os seres humanos, várias são causadas ou 
por uma disfunção fisiológica ou por uma exposição a um fator ambiental. Subjacente a 
muitas das condições a nível molecular está uma variação na quantidade, função ou atividade 
de uma ou mais proteínas, que desencadeiam alterações a nível celular, tecidular ou na função 
de um órgão. Grande parte da atual investigação médica mundial está voltada para a 
identificação de proteínas-chave envolvidas em mecanismos molecular subjacentes a muitas 
doenças, a fim de selecionar uma destas proteínas como alvo para o desenvolvimento de um 
novo medicamento que possa minimizar ou eliminar os sintomas. 
Em 1980 a indústria biofarmacêutica tornou-se sinónimo de proteínas terapêuticas 
produzidas por tecnologia de ADN recombinante, graças ao progresso no campo da 
biotecnologia que culminou com o surgimento do primeiro organismo geneticamente 
manipulado. Este progresso permitiu ainda o desenvolvimento de novas terapias bem como a 
produção em larga escala de bioprodutos que anteriormente só estavam disponíveis em 
quantidades limitadas, fazendo com que a maior parte das moléculas com potencial 
terapêutico propostas hoje em dia sejam à base de proteínas.  
A formulação de proteínas depende do conhecimento das suas características 
físico-químicas e biológicas, incluindo a estabilidade química e física, imunogenicidade e 
perfil farmacocinético. A atividade terapêutica das proteínas é altamente dependente da sua 
estrutura conformacional. No entanto, a estrutura da proteína é flexível e sensível às 
condições externas, o que significa que a sua produção, formulação e manipulação requer uma 
atenção especial na otimização da eficácia e segurança, incluindo a minimização da resposta 
imune. 
Apesar dos progressos da biotecnologia no desenvolvimento de novos medicamentos à 
base de proteínas, estes continuam a ter indicação para administração parenteral, devido às 
suas incompatibilidades e especificidades da estrutura química. No entanto, a via parenteral 
apresenta desvantagens relevantes para o paciente no que respeita o seu conforto e 
complacência, especialmente no tratamento crónico, onde se verifica uma diminuição na 
aderência ao tratamento, prejudicando assim o resultado desejado. Muitos esforços de 
pesquisa estão a ser realizados no sentido de aumentar a complacência do paciente pelo 
tratamento, quer através da utilização de vias alternativas de administração, ou na redução da 
frequência das injeções. Hoje em dia, várias superfícies mucosas, tais como a nasal, 
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pulmonar, oral e cavidade bucal estão a ser amplamente exploradas como vias alternativas 
para a administração de fármacos e macromoléculas. As nanopartículas emergem então como 
potencial aplicação na administração de substâncias terapêuticas, a fim de aumentar a 
eficiência do transporte e melhorar o perfil de libertação do fármaco. As vantagens da 
utilização de nanopartículas inclui a libertação da substância controlada e/ou prolongada, a 
redução de efeitos adversos associados com a substância, proteção contra compostos de 
inativação antes de chegar ao local de ação, aumentando assim a penetração intracelular do 
principio farmacológico. Alguns destes veículos possuem tamanhos subcelulares que 
permitem a internalização das partículas, podendo ocorrer a libertação do fármaco dentro da 
célula. Contudo estes veículos também acarretam desvantagens, como, limitação na 
capacidade de co associação a outras moléculas igualmente ativas, perfil toxico desconhecido, 
forma física indefinida. Para além da limitação no que diz respeito a encapsulação do 
fármaco, estes veículos podem também agregar ou degradar prematuramente devido à sua 
instabilidade em alguns fluídos biológicos 
O sucesso de uma formulação depende da capacidade da proteína em manter a sua 
estrutura nativa e atividade durante a preparação e a libertação após administração, bem como 
durante o período de armazenamento. Diferentes métodos são utilizados para a preparação de 
nanopartículas, que permitem a modulação da sua estrutura, composição e propriedades 
físico-químicas. Diferentes perfis de libertação do fármaco podem ser conseguidos usando 
diferentes sistemas nanoparticulados, tais como micro ou nano partículas poliméricas. 
A escolha do método de preparação das nanopartículas depende do polímero, da 
solubilidade do fármaco a ser encapsulado e da função que se quer atribuir ao sistema. A 
preparação de nanopartículas poliméricas pode envolver o uso de solventes orgânicos e 
métodos agressivos para biomoléculas. A utilização de polímeros naturais na construção 
destes veículos de entrega pode ultrapassar estes problemas, pois as nanopartículas podem ser 
formadas por simples complexação polielectrolítica. Polímeros naturais oferecem a vantagem 
de serem muito semelhantes, frequentemente idênticos, às substâncias macromoleculares, que 
os sistemas biológicos estão preparados para reconhecer e metabolizar. Assim os problemas 
de toxicidade e de estímulo crónico da reação inflamatória, bem como a falta de 
reconhecimento pelas células, provocados por muitos polímeros sintéticos, podem assim ser 
suprimidos. Esta semelhança a substâncias naturais ocorrentes, permite a conceção de 
sistemas de entrega que funcionam biologicamente a nível molecular, em vez de, 
macroscópico, revelando, por vezes, características únicas capazes de ultrapassar alguns dos 
problemas inerentes à administração de proteínas por vias não parenterais. Por outro lado, os 
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polímeros naturais apresentam frequentemente resposta imunológica e a sua manipulação 
tecnológica é mais complicada do que a dos polímeros sintéticos, devido à sua complexidade 
estrutural. Industrialmente estas formulações de sistemas de entrega de proteínas não são 
muito rentáveis devido à baixa eficiências de encapsulação (EE) que ronda normalmente os 
10%. 
 
Neste estudo foi então proposto o uso de polímeros naturais para a produção de 
nanopartículas para administração por vias mucosas, não só por esta classe de materiais 
apresentar mais possibilidade de cumprir os requisitos de biodegradabilidade e 
biocompatibilidade, que são obrigatórios em qualquer aplicação biomédica mas também pelas 
características únicas destes polímeros que podem aumentar a eficácia do tratamento por estas 
vias. Foram então escolhidos dois polímeros naturais fucoidan e quitosano, respetivamente 
extraídos de algas castanhas (Fucus vesiculosus), com 95% de fucose ésteres sulfatados 
(polissacárido aniónico), e do exosqueleto de crustáceos através da desacetilação da quitina 
(polissacarídeo catiónico). O quitosano destaca-se ainda pelas suas propriedades, muco-
adesiva e de perturbação transiente das junções célula-célula, aumentando assim a absorção 
do fármaco. 
Embora a técnica de complexação polielectrolítica tenha sido aplicada em outras ocasiões 
para a obtenção de nanopartículas à base de quitosano por interação com contra-iões, tais 
como o tripolifosfato ou carragenina, o presente trabalho é um dos primeiros a relatar a 
produção de nanopartículas resultante da complexação entre o quitosano e fucoidan. Estudos 
anteriores a este trabalho que relatam a complexação entre fucoidan e o quitosano, descrevem 
a produção de nanopartículas para encapsulação de curcumina um fármaco anti-tumor, ou o 
uso de micropartículas vazias (Fucospheres
®
) para tratamento de queimaduras dérmicas, 
tornando este estudo o primeiro a relatar a produção de nanopartículas para a encapsulação 
proteínas. 
Neste trabalho, foram preparadas nanopartículas fucoidan/quitosano (FUC/CS) por 
complexação polielectrólitica. A formação de nanopartículas foi confirmada pela visualização 
do efeito de Tyndall, característico da formação de suspensões coloidais. O tamanho e 
potencial zeta das nanopartículas foram medidos por espectroscopia de correlação de fotões e 
anemometria de laser Doppler, respetivamente, utilizando uma Nanoseries Zetasizer (Malvern 
Instruments
®
, UK). Várias razões FUC/CS de massa (4/1 a 1/4) foram desenvolvidas, que 
resultaram na criação de nanopartículas com diferentes tamanhos (338-676 nm) e potenciais 
zeta (+41 a -49 mV). Em seguida foram selecionadas as formulações que apresentavam as 
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características mais apropriadas para a encapsulação de biomoléculas 4/1 e 1/4. As 
características chave que fazem com que uma formulação de nanopartículas seja adequada 
para encapsulação de biomoléculas são, um tamanho pequeno e carga elevada (+/-) de modo a 
promover a interação com as células, bem como um fraco efeito de Tyndall que facilita a 
posterior resuspensão. Ao encapsular as biomoléculas as nanopartículas tendem a aumentar de 
tamanho e a perder carga (+/-), pois as cargas superficiais dos polímeros que estariam livres 
são neutralizadas pelas interações polímero-proteína, resultando num aumento do rendimento 
de produção e efeito de floculação. Neste estudo, a albumina de soro bovino, insulina e 
ovalbumina foram utilizadas como proteínas modelos. A BSA foi escolhida para testar as 
variáveis de encapsulação, pois é muito utilizada em investigação como proteína modelo. 
Com pI 4.7 de este modelo proteico permite a manipulação da sua carga superficial e 
consequentemente da interação com os polímeros. Tecnicamente esta manipulação traduz-se 
na incorporação prévia da BSA numa das soluções poliméricas fucoidan ou quitosano, o que 
lhe confere carga positiva ou negativa, ou na alteração na ordem de adição dos polímeros o 
que permite a manutenção de um dado pH por mais algum tempo, visando assim um aumento 
na EE. A eficiência de encapsulação das nanopartículas foi determinada indiretamente, 
mediante a quantificação da biomolécula não encapsulada presente no sobrenadante após o 
procedimento de isolamento das nanopartículas. A quantidade de biomolécula livre foi 
determinada por Cromatografia Líquida de Alta Pressão HPLC (Agilent
 ®
 série 1100, 
Alemanha) com uma coluna 3,6 Aeris u Widepore colum XB-C18 (Phenomenex 
®
, EUA). 
Todas as nanopartículas FUC/CS 4/1 apresentaram um excelente EE de cerca de 100%. A 
influência das variáveis foi mais pronunciada na FUC/CS 1/4 em que a pré-incorporação de 
BSA no fucoidan aumentou o EE em ambos protocolos A e B (55 e 87%), relativamente à 
pré-incorporação no quitosano (11 e 19%). Foi também avaliada a morfologia das 
nanopartículas FUC/CS 1/4 e 4/1 por TEM, assim como o rendimento de produção das 
partículas vazias e cheias e capacidade de associação da BSA por gravimetria. As 
nanopartículas FUC/CS apresentaram algumas variações em termos de tamanho e potencial 
zeta após 170 dias de armazenamento a 4 º C, mas as variações não comprometeram a 
aplicação pretendida como portadores de proteína para a administração da mucosa. 
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1 Introduction 
1.1 Biomolecule-based therapies 
 
1.1.1 Background 
 
The vastness of diseases that commonly affect humans are caused by either some 
physiological dysfunction resulting from a gene mutation, incorrect expression of the related 
protein, or to the exposure to an environmental factor, such as pesticides, diet, bacterial, 
fungal or viral infection. For many of the conditions at a molecular level underlies a change in 
the amount, function or activity of one or more proteins which triggers changes in cellular, 
tissue or organ function [1]. An example of common physiological dysfunction is diabetes, 
caused by an insufficient activity of insulin or lack of the protein, and often a combination of 
these two factors [2]. This disease is common throughout the world and reports reveal that in 
2011, 366 million people were affected with diabetes and in 2030 this number is expected to 
rise to 552 million. The highest incidence of diabetes is between 40 and 59 years and 78 000 
children develop type 1 diabetes per year [3]. A large part of current worldwide medical 
research aimed at the identification of key proteins involved in molecular mechanism 
subjacent to many diseases such as the various forms of cancer and neurological conditions 
such as Parkinson’s disease, motor neuron disease and multiple sclerosis, in order to select 
one of these proteins as a target for the development of a new drug that can minimize or 
eliminate the symptoms [1]. 
  
 
1.1.2 Historical frame  
 
During the 1980s biopharmaceutical drugs became synonymous of therapeutic proteins, 
vaccines, and hormones produced by recombinant DNA technology. A couple of years later, 
human insulin, developed by Genentech Company (USA), reached the market, stating the 
industrial application of this technology [4] . Since then, hundreds of research centers and 
enterprises worldwide have been engaged in research, development and production of 
biopharmaceuticals. [5] In the 25 years of existence of the biopharmaceuticals market, many 
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diseases have been and remain the focus of attention both for the development and production 
of medicines, mainly for cancer, hepatitis, diabetes, growth disorders and hemophilia [6]. In 
this regard, progress in the biopharmaceutical technologies has created an increasing interest 
in proteins and peptides due to their role in many pathologies. However, the use of these 
molecules in medicine has been limited by their low bioavailability, which results from low 
stability against proteolytic enzymes, hydrolytic degradation, low permeability, and the short 
half-life in systemic circulation [7]. At the same time, biotechnology appeared as a 
multidisciplinary science, gathering basic biological sciences such as genetics, microbiology 
and biochemistry, with chemistry, biological engineering and bioinformatics [8]. This 
combined expertise led to the development of new therapies and also the large scale 
production of bio-products that were previously available only in limited quantities. Thanks to 
this biotechnological breakthrough, most of the molecules with therapeutic potential proposed 
nowadays are protein-based [9]. 
 
 
1.1.3 Protein formulations  
 
Commercially, most protein-based drugs are formulated as aqueous solutions or 
suspensions ready for use or as lyophilized powder for reconstitution of the product. The 
formulation of proteins depends on their physicochemical and biological characteristics, 
including chemical and physical stability, immunogenicity and pharmacokinetic profile [10]. 
Therapeutic activity of proteins is highly dependent on their conformational structure. 
However, the protein structure is flexible and sensitive to external conditions, which means 
that its production, formulation and manipulation require special attention on optimizing the 
efficacy and safety, including minimizing the immune response [11]. From a design 
perspective, proteins are complex and challenging molecules to develop drug delivery 
systems. The success of a formulation depends on the ability of the protein to maintain its 
native structure and activity during the preparation and release after administration, as well as 
during the storage period [12]. Some proteins require sustained release, while others require a 
controlled, immediate or pulsed release. Different release profiles can be achieved using 
different particulate systems for drug delivery, such as polymeric micro or nano particles, 
hydrogels, liposomes and emulsions [13]. 
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In order to develop these new systems several proteins are used as models in research. In 
the context of this work, it is important to highlight bovine serum albumin (BSA), ovalbumin 
and insulin. BSA has been primarily used in molecular studies and in the formulation of 
protein-based drug delivery systems [14]. The extensive use of this protein as model is due to 
its easy dissolution in water, yet it is relatively resistant to digestion. Presenting an isoelectric 
point of 4.7 this protein might expose negative or positive charges when in basic or acid 
environments, respectively. [15]. With a theoretical molecular weight of 69.3 kDa this protein 
has a well studied and documented structure that consists of nine loops connected by 17 
disulfide bridges that are protected in the core of the protein. Relatively abundant and cheaper 
than other proteins, BSA also presents years of stability when stored at 2-8°C. Ovalbumin 
shares many of these characteristics and, therefore, is also frequently used as model [16]. In 
parallel, insulin is also used as model peptide, having the great advantage of providing a 
measurable pharmacological effect and being, thus, used as model therapeutic peptide.  After 
insulin discovery, researchers engaged in the finding of different modes and routes of 
administration for this protein [12]. 
 
 
1.2 Routes of administration for protein-based formulations 
 
Despite the great biotechnology progress, delivering the new protein-based drugs remains 
a problem, mainly due to incompatibilities and specific chemical structure [17]. Because of 
this, most protein-based formulations have an indication for parenteral administration. 
However, the parenteral route has important disadvantages to the patient, especially in chronic 
therapy, which decreases therapeutic compliance, thus impairing the expected results [18]. 
Many research efforts are being made to improve patient compliance, either through the use 
of alternative routes of administration or by reducing the frequency of injections [19]. The 
demand for better ways for the administration of proteins has resulted in research for the 
development of new pharmaceutical technologies. In this regard, the industry interest in 
developing alternative methods for drug delivery has been growing for years [6]. Nowadays, 
several mucosal surfaces such as the nasal, pulmonary and oral are being extensively explored 
as alternative routes for the systemic administration of macromolecular drugs [20].  
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1.2.1 Gastrointestinal mucosa 
 
The oral route is the preferred for drug administration, being the most widely used. Apart 
from the simplicity of the administration itself, this approach provides access of the drug to 
the intestinal epithelium, the greater and the most specific surface area (200 m
2
) of absorption 
existing in the human body (Figure 1.1) [21]. A major limitation in oral protein administration 
relates to the inherent instability due to inactivation or rapid enzymatic and pH degradation of 
these molecules in the gastrointestinal tract, in addition to the low permeability through 
biological membranes due to the high molecular weight and polar surface characteristics [22]. 
 
 
Figure 1.1: Drug (green) distribution in the digestive system trough oral administration. 
Adapted from [23]. 
 
 
1.2.2 Buccal mucosa 
 
The buccal mucosa has attracted particular attention due to its unique physiological 
features, such as the avoidance of presystemic elimination, including the first pass effect, 
although this surface presents a relatively small area available for absorption (50 cm
2
) [24]. 
The oral cavity presents 3 different types of mucosa (Figure1.2), with extremely vascularized 
epithelium that, combined with a low and very specific enzymatic activity, makes the buccal 
mucosa a great site for protein absorption [20]. 
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Figure 1.2: Buccal mucosa for drug absorption [20]. 
 
 
1.2.3 Pulmonary mucosa 
 
The large alveolar surface area (100 m
2
) suitable for drug absorption (Figure 1.3), 
presents a low thickness epithelial barrier, extensive vascularization and relatively low 
proteolytic activity compared to other administration routes. Together with the absence of the 
first-pass effect, this makes the pulmonary delivery of peptides and proteins an outstanding 
possibility [25].  
 
 
Figure 1.3: Drug (green) distribution for pulmonary administration. Adapted from [26]. 
 
Insulin is undoubtedly the biopharmaceutical prototype and Exubera
®
 (Pfizer) (Figure 
1.4) was the first inhaled formulation approved by the United States Food and Drug 
Administration (FDA), for pulmonary administration of insulin in a dry powder form. Inhaled 
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insulin showed to be effective, well tolerated and better accepted in patients with type 1 and 
type 2 diabetes [27]. However, this technology was removed from the market. The patients 
claimed that the increased price of Exubera
®
 relatively to the common injectable insulin was 
worthless and that the needles have gotten so fin that they cause virtually no pain. Moreover 
the patients also claimed that was not so easy to dose insulin with Exubera
®
 as it was with the 
inject one. [28] 
 
 
Figure 1.4: Insulin formulation for pulmonary administration. [29] 
 
 
1.2.4 Nasal mucosa 
 
The nasal mucosa (Figure 1.5) is also receiving a great deal of attention due to its 
permeability and easy access to the drug absorption site, although it presents low surface area 
(160 cm
2
). This route is already commonly used for delivery of drugs for treatment of local 
diseases such as nasal allergy, nasal congestion and nasal infections [30]. A wide range of 
products has been developed mostly aiming at the advantage of the rapid onset of action for 
the treatment of pain and erectile dysfunction. Recent developments had brought this route as 
an alternative for direct administration of drugs in to the brain for the treatment of Alzheimer 
and Parkinson [31]. 
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Figure 1.5: Drug (green) distribution in nasal administration. Adapted from [32]. 
 
 
1.3 Transmucosal drug delivery technologies 
 
To overcome the limitations created by the mucosal surfaces, several strategies were 
developed aiming at improving the bioavailability of therapeutic proteins. The approaches 
commonly used in formulating mucosal protein delivery systems include specific excipients, 
such as absorption enhancers, enzyme inhibitors, and mucoadhesive polymers. In addition, 
formulations are designed in such a manner to provide protection of protein drugs from the 
harsh human environment [33]. These strategies have proven to improve protein 
bioavailability and researchers believe that addressing the mentioned drawbacks is possible 
with the design of a protein formulation that combines all of referred strategies (Table 1.1) 
[22].  
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Table 1.1: Main approaches used for mucosal protein delivery. Table adapted from [22]. 
Approaches Systems Advantages Disavantagens 
Absorption 
enhancers 
Bile salts, fatty acids, 
surfactants, salicylates, 
chelators, zonular occludens 
toxin 
Increase membrane 
permeation 
Transport of both 
protein/peptide and 
undesirable molecules  
 
Enzyme 
Inhibitors 
Sodium glycocholate, 
camostat mesilate, bacitracin, 
soybean trypsin inhibitor, 
aprotinin, CkOVM, DkOVM, 
polymer–inhibitor conjugates 
Resist enzyme 
degradation  
 
Induced severe side effects 
in chronic therapy 
Mucoadhesive 
Polymers 
P(MAA-g-EG) hydrogel and 
lectinconjugated alginate 
microparticles, thiolated 
polymers, 
Mucoadhesive patch system 
mucoadhesive polymer–
inhibitor 
Site-specific 
delivery and 
improve membrane 
permeation 
 
Site-specific drug 
delivery and resist 
enzyme degradation 
Natural mucus turnover in 
intestine 
 
Extensive costs of certain 
enzyme inhibitors 
Formulation 
Vehicles 
Emulsions 
Liposomes 
Microspheres 
Nanoparticles 
Protect drug from 
acid and enhance 
permeation through 
mucosa 
 
Improve physical 
stability and 
increase membrane 
permeation 
 
Prevent proteolytic 
degradation 
.  
 
Restrict release of 
drug to favourable 
area; 
 
Prevent enzymatic 
degradation and 
increase intestinal 
epithelial 
absorption 
Physicochemical instability 
in long-term storage and 
requirement for storage at 
low Temperatures 
 
Low stability of liposomes 
 
 
Concerns of protein 
stability during processing, 
release and storage 
 
Low loading efficiency of 
hydrophilic drugs, 
difficulty of precise size 
control and avoidance of 
particle aggregation 
Abbreviations: CkOVM, chicken ovomucoid; DkOVM, duck ovomucoid; P(MAA-g-EG), 
poly(methacrylic acid-g-ethylene glycol). 
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1.4 Polymeric nanoparticles for mucosal administration 
 
1.4.1 Historical frame 
 
Nanoparticles were first developed in the mid 70s in order to carry vaccines and 
anticancer agents to specific tissues or even cells improving therapeutic efficacy and 
decreasing the toxic effect of the drugs [34].  Later on, with the growing interest in the 
therapeutic potential of labile molecules such as protein and peptides, nanoparticles started 
being explored as vehicles to provide protection, being also proposed for administration 
through different routes, such as mucosal surfaces (Table 1.2). Nowadays, nanotechnology 
allows real progress in the achievement of temporal and spatial site-specific delivery [14]. 
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Table 1.2: Advantages and disadvantages of different mucosal routes and administration of 
nanoparticle through these routes [24] [35] [19]. 
Administration 
routes 
Advantages Disadvantages  
Oral  Drug protection against pH 
and enzymatic damage 
 Increased permeability 
across the epithelial 
membrane 
 First-pass metabolism in the 
liver: potential hepatotoxic effect 
 Potential translocation into 
systemic circulation 
 Requires intact intestinal mucosa 
for the uptake  
Buccal  Short recovery time of 
mucosa after stress or 
damage 
 Increased permeability to 
molecular weight and 
hydrophilic compounds 
 Limited to potent molecules 
 Continuous dilution of drug 
 Involuntary swallowing of drug 
Pulmonary  Ease of administration 
 Local action 
 Rapid absorption and onset 
of action 
 Possibility of administering 
lower doses 
 Local toxicity 
 Potential for translocation into 
systemic circulation 
 Airway structure acts as a filter 
 Mucociliary clearance 
 Alveolar macrophages 
 Absorption affected by 
pathological conditions 
 Requires complex devices and 
particles with specific 
aerodynamic properties 
 Particles can be exhaled 
 Many factors affecting 
reproducibility 
Nasal  Ease of administration  
 Rapid absorption and onset 
of action 
 Fewer side effects 
 Drug protection from 
degradation by nasal 
mucosa and secretion 
enzymes 
 
 
 Large interspecies variation, 
leading to difficult 
extrapolations of results 
 Drug diffusion limited by the 
mucus barrier and mucociliary 
clearance 
 Administered volume limited to 
25-200 μL 
 Molecular weight cut-off of ~ 1 
kDa 
 Absorption affected by 
pathological conditions 
 Limited to potent molecules 
 Lack of reproducibility 
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1.4.2 Definition and structural organization 
 
Nanoparticles present variable sizes that range between 10 and 1000 nm, in which the 
drug can be dissolved, coated, encapsulated or dispersed. Nanoparticulate drug delivery 
systems can have several terminologies, according to structures and materials composing the 
systems (Figure 1.6). The use of different production methods can create different and unique 
systems, which can be used according to the biological interaction necessary for each purpose 
[36]. In the context of this work, the importance of polymeric nanoparticles will be 
highlighted, considering their potential for the transmucosal administration of proteins [37]. 
 
 
Figure 1.6: Types of terminologies used for nanoparticulate drug delivery systems. (NPs) 
Nanoparticles [36]. 
 
Other systems such as microparticles and hydrogel are also being developed with the same 
propose of nanoparticles. Table 1.3 describes the advantages and disadvantages of the use of 
nanoparticles. .Nanoparticles can actually protect labile drugs from the biological barriers and 
enhance their absorption by optimizing their interaction with the absorption site.  Some 
authors have suggested that nanoparticles may improve the bioavailability of peptide or 
protein [7]. 
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Table 1.3: Nanoparticles as drug delivery systems, advantages and disadvantages .Adapted 
from [38] [24]. 
Advantages Disadvantages 
High surface/volume ratio 
Ease of surface modification 
Maximized contact with mucosa 
High drug concentration in desired 
site 
Reduction of adverse drug-
associated effects 
Intracellular penetration 
Protection of encapsulated 
molecules  
Possibility to provide controlled and 
or/ prolonged release 
Possibility of targeted delivery 
Enhanced drug absorption 
Undefined physical shape 
Limited capacity to co-associate other 
functional molecules 
Unknown toxicity profile 
Lack of suitable large-scale 
production methods 
Low stability in some biological 
fluids 
Tendency for aggregation 
Limited loading capacity (unsuitable 
for less potent drugs) 
Small size can provide access to 
unintended environments 
 
 
Polymeric nanoparticles are spherical systems, formed of one or more polymers 
[39].Polymeric nanoparticles are classified in two categories, nanospheres (Figure 1.7 A) and 
nanocapsules (Figure 1.7 B), which differ depending on the composition and structural 
organization. The nanocapsules are vesicular systems in which the drug is within an aqueous 
or oily cavity surrounded by a polymer membrane, or can also be found adsorbed in the 
polymer membrane. The nanospheres are formed by a polymeric matrix, where the drug is 
dispersed or adsorbed [40]. 
 
 
Figure 1.7: Structural differences for polymeric nanoparticles. (A) nanospheres, (B) 
nanocapsules. Adapted from [41]. 
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1.4.3 Preparation methods 
 
Different methods are used to prepare polymeric nanoparticles, which allow the 
modulation of their structure, composition and physicochemical properties [42]. The choice of 
a preparation method depends on the final application of the produced system, type of 
polymer and the solubility of the drug to be encapsulated. The preparation of polymeric 
nanoparticles often involves the use of organic solvents and aggressive methods, like 
ultrasound energy. However, these could affect negatively both the drug/protein to be 
encapsulated and the organism that will be administered with the nanosystem. Different 
methods are available which explore different polymer interactions, resulting in techniques 
such as ionic gelation, polyelectrolyte complexation, emulsification, coacervation and 
spontaneous self-assembling, among others [43]. Using natural polymers to prepare the 
nanoparticles permits using methodologies that overcome the mentioned problems regarding 
aggressive conditions, one of the most used techniques being polyelectrolyte complexation 
[44].  
 
 
1.4.4 Characterization 
 
Complete characterization of nanoparticles requires assessment of several parameters: 
polymer type and concentration, morphology, particle size and zeta potential, production 
yield, protein encapsulation efficiency, protein loading capacity and type of release profile 
[25]. Nanoparticle formulation depends on the choice of suitable polymeric systems with high 
encapsulation efficiency, improved bioavailability and retention time. The desired 
formulations are generally achieved by trial and error method. Nanoparticle formulations 
display improved properties as compared with conventional formulations, namely concerning 
controlled release, targeted delivery and therapeutic impact. These targeting capabilities of 
nanoparticles are influenced by particle size, surface charge, surface modification, and 
hydrophobicity [45]. The size of nanoparticles for crossing different biological barriers is 
dependent on the tissue, target site and circulation. Therefore, size and size distribution 
determines nanoparticle interaction with the cell membrane and their penetration across the 
physiological drug barriers (Figure 1.8). In turn, nanoparticle surface charge is important in 
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determining whether they would cluster in biological fluids or would adhere to, or interact 
with oppositely charged cells, predicting cellular internalization [39]. 
 
 
Figure 1.8: Size influence on deposition of inhaled nanoparticles in the human respiratory 
tract [46]. 
 
 
1.5 Polymers as nanoparticle matrix-forming materials  
 
1.5.1 Definition 
 
A polymer is a high molecular weight molecule composed of repeating small subunits 
called monomers. The polymers may be classified according to their occurrence as natural or 
synthetic, as well as for their chain nature, structure, morphology and type of polymerization 
reaction. Natural polymers have in general more complex structures than synthetic polymers 
[47]. Both natural and synthetic polymers have been extensively investigated as biomaterials, 
those with the most frequently reported applications being described in Table 1.4, with their 
respective advantages and disanvantages. 
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Table 1.4: Different types of polymers  and respective advantages and disadvantages [48]. 
Occurrence  Polymers Advantages Disadvantages 
Natural Proteins 
Polynucleotides 
Polysaccharides 
Gums 
Resins 
Elastomers   
Biodegradable 
Biocompatible 
Nontoxic 
Function biologically 
at molecular and 
macroscopic level. 
Degradation via 
natural enzymes; 
cross-linkers can 
make less degradable 
Biodeterioration 
Immunological 
reaction 
High natural 
variability 
Structurally 
complexity  
Technological 
manipulation is more 
elaborate 
 
Synthetic Polyamides 
Polyamine acids 
Polyalkylated 
cyanoacrylates 
Polyesters 
Poly(ortho esters) 
Polyurethanes 
Polyacrylamides 
Predictable properties 
Batch-to-batch 
uniformity 
Easy technological 
manipulation 
 
Too expensive 
Environmental and 
human health concerns 
Lack of recognition by 
cells 
Toxicity 
Stimulation of a 
chronic inflammatory 
reaction 
 
 
1.5.2 Application of natural polymers in nanopharmaceutics 
 
For a polymer to be used as a biomaterial it should not cause inflammatory or toxic 
reactions at the application site, it must provide the drug with adequate half-life , degradation 
time should be compatible with the desired application, degradation products cannot be toxic, 
and should be able to be metabolized and eliminated from the body [49].  
Natural polymers may be regarded as the first clinically used biomaterials and, actually, 
polymers have always been classical excipients in pharmacy. More recently, with the 
advances in nanotechnology, more sophisticated biodegradable polymers were developed 
providing new delivery systems for peptides and proteins [48]. However, the development of 
biodegradable systems requires the control of a great number of variables, since the kinetics 
of polymer degradation in vivo must remain constant, to obtain a controlled release of the 
substance. Therefore, factors such as pH and temperature, which may promote an increase or 
a reduction in the rate of degradation of the system, should be evaluated during development 
[50]. Synthetic biodegradable polymers have shown growing interest in the application as 
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delivery systems, since natural ones feature, usually, a rapid drug release [51]. The profile and 
mechanism of drug release depends on the nature of polymer and also the physicochemical 
properties of the substance incorporated therein [49].  
 
 
1.5.3 Chitosan 
 
Chitosan is a cationic polysaccharide obtained by the alkaline, partial deacetylation of 
chitin, the major component of crustacean shells [52]. This linear copolymer consists of 
β-(1-4)-linked 2-amino-2-deoxy-D-glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-
glucose (N-acetyl-D-glucosamine) units, which are displayed in figure 1.9. Due to the content 
of primary amino groups in the main backbone, this polysaccharide presents cationic 
character. Chitosan is easily soluble in aqueous acidic solutions, featuring a low solubility at 
the physiological pH of 7.4 as it is a weak base (pKa around 6.5) [53].  
  
 
Figure 1.9: Chitosan structure [54]. 
 
As the main characteristics justifying its wide use in pharmaceutical applications, it is 
worth mentioning the biodegradability, biocompatibility and also the strong mucoadhesive 
properties. Along with the very safe toxicity profile, these make chitosan an exciting and 
promising excipient for the pharmaceutical industry for present and future applications [55]. 
These unique features allowed the design of bioadhesive drug carrier systems that have arisen 
as promising candidates in several mucosal administration routes, thus improving the 
transport of biomacromolecules such as peptides, proteins, oligonucleotides, and plasmids 
across biological surfaces [56]. Chitosan particles can also improve drug absorption via the 
paracellular route, as exemplified in figure1.10. The mechanism of action of chitosan has 
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been suggested to be a combination of bioadhesion and a transient widening of the tight 
junctions between epithelial cells [57]. 
 
.  
Figure 1.10: Effect of chitosan on the absorption of drugs by the paracellular route. (A) 
Normal epithelium. (B) Transient disruption of tight junctions by chitosan with enhancement 
of drug absorption. 1: represents the drug, 2: represents the tight junction. Adapted from [57]. 
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1.5.4 Fucoidan 
 
Fucoidans are anionic polysaccharides containing substantial percentages of L-fucose and 
sulfate ester groups, extracted from brown algae and some marine invertebrates such as 
marine cucumber. Commercially available, fucoidan prepared from Fucus vesiculosus 
contains 44% fucose and 26% sulfate, being water soluble [58]. A structural model in figure 
1.12 shows that the core region of fucoidan is primarily α-L-fucose units linked by (14) and 
(13) glycosidic bonds, with sulfate groups substituted at the C-4 position on some of the 
fucose residues. (Figure 1.11) [59].  
 
 
 
 
For the past decade, fucoidans isolated from different species have been extensively 
studied due to their varied biological activities, including anticoagulant and antithrombotic, 
antivirus, antitumor and immunomodulatory, anti-inflammatory, antidislipidemic, antioxidant 
and anticomplementary properties. Relevant activity was reported against hepatopathy, 
uropathy and renalpathy, as well as providing gastric protective effects and therapeutic 
potential in surgery. Fucoidan can showed the ability to sequester toxic heavy metals such as 
Cd
2+
,Cu
2+
, Zn
2+
, Pb
2+
, Cr
3+
, and Hg
2+
. This marine biopolymer has shown great properties for 
drug delivery and has been reported to bind type A I and II transmembrane glycoprotein 
receptors found in macrophages, this way fucoidan can promote specific interactions of a drug 
carrier with the macrophages [60].  
  
Figure.1.11: Fucoidan structure [71]. 
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1.6 State of the Art 
 
Although the technique of polyelectrolyte complexation was applied in other occasions to 
obtain chitosan-based nanoparticles by interaction with counter-anions, such as 
tripolyphosphate or carrageenan [61], [52], the present work is one of the first reports on the 
production of nanoparticles resulting from the complexation between chitosan and fucoidan. 
Previous reports on fucoidan/chitosan complexation describe the production of nanoparticles 
to encapsulate the antitumor drug curcumin [62], as well the production of microparticles for 
protein encapsulation [63] or the use of unloaded microparticles (Fucospheres
®
) for dermal 
burn treatment [59], making this study the first that reports fucoidan/chitosan nanoparticles 
for protein encapsulation. Importantly, the results reported in the present study have already 
been presented in panel at the 3
rd
 Congress of the Portuguese Society of Pharmaceutical 
Sciences (Appendix 1) and 9
th
 Central European Symposium on Pharmaceutical Technology 
(Appendix 2).  
 
2 Objectives 
 
The aim of this work was to verify de ability of chitosan and fucoidan to assemble into 
nanoparticles which display ability to encapsulate different model proteins, namely BSA, 
ovalbumin and insulin. The nanoparticles are aimed at an application in systemic mucosal 
protein administration and, therefore, several specific properties should be evidenced, as 
follows: 
- Size within 50-500 nm to permit a close interaction with the epithelial surface; 
- Zeta potential above 30 mV (either negative or positive) to provide adequate stability in 
aqueous suspension and to maximize interaction with the epithelial surface; 
- Adequate protein encapsulation efficiency, preferably above 50%. 
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3 Materials and Methods 
 
3.1 Reagents 
 
Chitosan (CS) (low molecular weight, deacetylation degree 75–85%), Fucoidan (FUC) 
from Fucus vesiculosus, bovine albumin serum (BSA), insulin and ovalbumin sodium, 
phosphotungstate dibasic hydrate, sodium hydroxide and glycerol were purchased from 
Sigma-Aldrich
®
 (Germany). Bradford reagent was purchased from Bio-rad
®
 (Germany) 
Trifluoroacetic acid (TFA) and glacial acetic acid were supplied, respectively, by Alfa Aesar
®
 
(Germany) and Panreac Synthesis
®
 (Germany). Ultrapure water (Integral 3, Millipore
®
, 
Portugal) was used throughout. All other chemicals were reagent grade. 
 
 
3.2 Preparation of fucoidan/ chitosan nanoparticles  
 
Fucoidan/chitosan (FUC/CS) nanoparticles were prepared by polyelectrolyte 
complexation, in which the negatively charged groups of fucoidan interact with the cationic 
groups of chitosan, creating electrostatic bonds. Briefly, a 2 mg/mL stock solution of FUC 
(pH 6.18) was prepared with milliQ water and a 1 mg/mL stock solution of CS (pH 3.17) was 
prepared with 1% (w/w) acetic acid. Both solutions were filtered before further using (0.2 µm 
filter, Whatman
®
, Germany). These stock solutions were then diluted to obtain various 
concentrations, in order to permit the preparation of nanoparticles with different mass ratios 
(4/1 to 1/4, w/w). FUC/CS nanoparticles were spontaneously formed by drop wise addition of 
either 1 mL of FUC into 1 mL of CS solution (protocol A), or 1 mL CS into 1 mL of FUC 
solution (protocol B), under magnetic stirring for 10 min, at room temperature.  
Nanoparticle suspensions were then placed in eppendorf tubes over a layer of 10 µL 
glycerol that prevents nanoparticle dehydration and aids the subsequent resuspension step. 
Nanoparticles were isolated by centrifugation at 16000 g, for 30 min at 15 ºC (Thermo 
Scientific
®
, Germany). The supernatants were discarded and nanoparticles were resuspended 
in 200 µL of purified water.   
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3.3 Association of biomolecules to FUC/CS nanoparticles 
 
Three different proteins were associated to the nanoparticles, which were used as models: 
bovine serum albumin (BSA), insulin and ovalbumin. BSA and ovalbumin were dissolved in 
milliQ water, while insulin was dissolved in NaOH 0.01 M. The proteins were either 
associated with FUC or CS prior to the mixture of the polymers, to test the effect of this 
variable. Along this text, when referring to a nanoparticle formulation loaded with proteins, 
an asterisk (*) will be placed close to the number representing the polymer with which the 
protein was mixed prior to nanoparticle formation (example: FUC/CS = *4/1 means that the 
protein was mixed with the FUC solution prior to pouring of this polymer into the CS 
solution).  
The proteins were associated to the nanoparticles in a concentration of 30% (w/w) 
respective to the polymer with the higher content in the formulation. Both protocols A and B 
(described above) were used to prepare protein-loaded FUC/CS nanoparticles, in order to test 
the effect of the order of addition of polymers on the final characteristics of the nanoparticles. 
The isolation of nanoparticles was performed as described above. 
 
 
3.4 Characterization of nanoparticles 
 
3.4.1 Physicochemical properties 
 
The size and zeta potential of nanoparticles were measured by photon correlation 
spectroscopy and laser Doppler anemometry, respectively, using a Zetasizer Nanoseries 
(Malvern Instruments
®
, UK). For the measurements, 20 µL of each sample were diluted with 
1 mL purified miliQ water and the suspension placed in an electrophoretic cell. Each analysis 
was performed at 25 ºC (n = 3). 
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3.4.2 Morphology  
 
The morphological analysis of FUC/CS nanoparticles was performed by transmission 
electron microscopy (TEM; Jeol-JEM
®
 1011, Germany). Concentrated nanoparticle 
suspensions were obtained upon centrifugation, mounted on copper grids coated with a 
carbon film (Ted Pella
®
, USA) and stained with a 2% (w/v) sodium phosphotungstate dibasic 
hydrate solution.  
 
 
3.4.3 Determination of nanoparticle production yield 
 
The nanoparticle production yield was determined by gravimetry. For this procedure, 
nanoparticles were prepared,  isolated by centrifugation at 16000 g, for 30 min at 15 ºC 
(Thermo Scientific
®
, Germany)  and the sediments were freeze-dried over 24 h, using a 
Freeze Dryer (Labconco
®
, USA) (n = 6). The production yield (PY) was calculated as 
follows:  
 
      
                   
                  
     
 
Where nanoparticles weight is the sediment weight after freeze-drying and total solids 
weight is the total amount of solids added for nanoparticle formation (fucoidan and chitosan 
for unloaded nanoparticles and fucoidan, chitosan, and protein for protein-loaded 
nanoparticles).  
 
 
3.4.4 Stability assay 
 
For the assessment of nanoparticle stability, the formulations FUC/CS 1/4 and 4/1 were 
prepared according to the procedure described above. Aqueous suspensions of nanoparticles 
were stored at 4 ºC and their size and zeta potential were monitored along time (n > 3).  
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3.4.5 Determination of BSA encapsulation efficiency and loading capacity of 
nanoparticles 
 
The BSA encapsulation efficiency was determined indirectly, by quantification of the 
non-encapsulated protein present in the supernatant after the nanoparticle isolation procedure. 
The amount of free protein was primarily determined by High Pressure Liquid 
Chromatography (HPLC, Agilent
®
 1100 series, Germany) with a  Aeris Widepore 3.6 u XB-
C18 column (Phenomenex
®
, USA). The conditions for each run were: temperature 25 ºC; 
gradient flow (0.1% TFA in water (A), 0.1% TFA in acetonitrile (B); A/B from 95:5 to 35:65 
in 15 min) mobile phase, total run time 20 min, UV detection at 280 nm; flow rate 1.0 
mL/min; injection volume 20 µL; BSA retention time 8.7 min. A linear calibration curve for 
BSA in 1% (w/w) acetic acid was obtained over the range 5–120 µg/mL (n = 3) (R2 = 0.996). 
Absorbance spectrums of pure solutions of polymers and BSA were run in So Bio UV-Visible 
spectrophotometer (Varian
®
, Australia). The nanoparticle protein association efficiency and 
loading capacity were calculated from Equations indicated below: 
 
                             
                                          
                     
     
 
 
 
                     
                                        
                   
     
 
 
 
3.5 Statistical analysis 
 
The t-test and the one-way analysis of variance (ANOVA) with the pairwise multiple 
comparison procedures (Student–Newman–Keuls method) were performed to compare two or 
multiple groups, respectively. All analyses were run using the SigmaStat
®
 statistical program 
(Version 3.5, USA) and differences were considered to be significant at a level of P < 0.05. 
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4 Results and discussion 
 
4.1 Characterization of FUC/CS nanoparticles 
 
Fucoidan/chitosan (FUC/CS) nanoparticles were successfully obtained, using several 
concentrations of the two polymers, which resulted in FUC/CS mass ratios of 1/4 to 4/1. The 
assembly of nanoparticles was mediated by an electrostatic interaction between the negatively 
charged sulfate groups of fucoidan and the oppositely charged amino groups of chitosan. The 
order of addition of the polymers was analysed as variable, varying according to Protocols A 
(fucoidan added over chitosan) and B (chitosan added over fucoidan), as was described in the 
methodology. Further optimizations of the procedure of nanoparticle preparation are 
described in appendix 3. Apart from the visible Tyndall effect that proves the formation of a 
colloidal suspension of FUC/CS nanoparticles, the effect of different mass ratios and order of 
addition of polymers was evaluated concerning the resultant size, zeta potential and 
production yield, as described in the following sections. 
 
 
4.1.1 Morphological and physicochemical properties 
 
Figure 4.1 displays the TEM microphotographs of representative FUC/CS nanoparticles 
of mass ratios 4/1 and 1/4, which evidence a compact structure and a tendency to a spherical 
shape.  
 
Figure 4.1: TEM microphotographs representative of FUC/CS nanoparticles. FUC/CS = 1/4 
(A and B) and FUC/CS = 4/1 (C and D). 
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As displayed in Graphic 4.1, the size of FUC/CS nanoparticles varied between 338 and 
676 nm. As expected, the variation of mass ratios resulted in different sizes, an observation 
valid for both protocols A and B, although a particular trend could not be established. 
Generally, it was observed that the presence of greater amounts of polymer (chitosan and 
fucoidan) in the formulations resulted in increased particle size of the nanoparticles. 
Therefore, the formulation FUC/CS = 1/1 presented the highest sizes (p < 0.05), 564 and 676 
nm for protocol A and B, respectively. Accordingly, the opposite happens when the 
concentration of the polymers in each formulation reaches the lower limit, with the mass 
ratios of 4/1 and 1/4 presenting the lowest sizes in each protocol (varying from 338 to 456 
nm). This general behaviour can be observed for both protocols, as described. However, size 
differences were more prominent in protocol B, where nanoparticles displayed the lowest and 
the highest sizes. As a general trend, the order of addition of one polymer over the other 
affected the resulting nanoparticle size and, thus, different results were obtained for protocols 
A and B. When comparing both protocols, statistically significant differences were obtained 
in all the formulations (p < 0.05), except for mass ratios 1/2 and 1/4. For a more direct 
observation of the size values, a table with that information is available in appendix 4. 
 
 
Graphic 4.1: Size variation of FUC/CS nanoparticles of different mass ratios, produced using 
() protocol A and () protocol B (mean ± SD, n = 3). 
 
 
In what concerns the zeta potentials of the obtained FUC/CS nanoparticles, a complete 
shift from strong negative to strong positive charges was observed, depending on the mass 
ratios (graphic 4.2). Those formulations with higher amount of fucoidan (4/1 to 2/1) resulted 
in a negative charge, with a maximum of -37 mV registered for FUC/CS = 4/1. On the 
0 
100 
200 
300 
400 
500 
600 
700 
800 
4/1 3/1 2/1 1/1 1/2 1/3 1/4 
Si
ze
 (
n
m
) 
FUC/CS (w/w) 
26 
 
contrary, formulations with the higher amount of chitosan (1/2 to 1/4) displayed strong 
positive charge, reaching a maximum value of +49 mV.  Curiously, the formulation with 
equal mass of both polymers also registered a strong positive surface charge (+43 mV or +49 
mV, depending on used protocol), which indicates that chitosan has a higher charge density. 
The specific values obtained for each formulation and protocol are also available on table x on 
appendix 4. On the contrary of what was observed for the size, zeta potentials were not 
affected by the order of addition of polymers tested in protocols A and B. In addition, 
different mass ratios did not have a pronounced effect on zeta potential either, in contrast with 
what was observed for nanoparticle size.   
 
 
Graphic 4.2: Zeta potential variation on FUC/CS nanoparticles of different mass ratios, 
produced using () protocol A and () protocol B (mean ± SD, n = 3). 
 
It is a fact that a complete inversion of zeta potential (p < 0.05) is obtained when fucoidan 
changes from the most represented polymer, inducing a strong negative charge, to the less or 
equal represented polymer, in which cases a strong positive charge is obtained. However, 
apart from this evident shift, all formulations with higher amount of fucoidan (4/1 to 2/1) 
displayed a charge around -40 mV and all formulations from 1/1 to 1/4 registered a charge of 
approximately +45 mV. This effect was reported in several other works concerning chitosan-
based nanoparticles, in which similar variations of polymer mass ratios resulted in very small 
changes of zeta potential, in the order of 4 or 5 mV [64], [65]. 
Nanoparticles based on chitosan and fucoidan were previously proposed for the treatment 
of dermal burns [59] and for the encapsulation of stromal cell-derived factor 1 (SDF-1), 
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which is an important chemokine in stem cell mobilization [66]. In the first case, only 
positively charged nanoparticles were obtained, inclusive when fucoidan was present in 
higher amount (FUC/CS = 5/1). The authors justified this effect with the possible formation 
of an outer layer of chitosan that took place during the nanoparticle assembly [59]. The 
second work reported very similar results as compared to those described in the present study, 
with strong negatively charged nanoparticles being obtained when fucoidan is present in 
higher amount in the formulation (FUC/CS = 5/1 has -49.8 mV). Additionally, FUC/CS = 1/1 
also presents a positive charge (+ 24.5 mV), as is reported in the present study [66]. The 
explanation for the different results found among studies might rely on the use of different 
chitosan and fucoidan, which is available with very different characteristics and usual very 
few details are given in the papers. 
 
 
4.1.2 Nanoparticle production yield 
 
Given the displayed size characteristics, FUC/CS mass ratios of 4/1 and 1/4 were selected 
to proceed with the studies. At the beginning of this work, only Protocol A was in course for 
the preparation of nanoparticles and, when protein-loaded nanoparticles were prepared, the 
protein was always mixed with the polymeric solution corresponding to the lower amount in 
each formulation (fucoidan in FUC/CS = 1/4 and chitosan in FUC/CS = 4/1). Protocol B was 
tested later on in an attempt to improve the encapsulation efficiency of nanoparticles with 
mass ratio 1/4. This is why protocol B was not tested for formulation 4/1 concerning the 
production yield, as the characteristics of those nanoparticles were satisfactory.  
Table 4.1 shows that protocol A tends to provide a higher production yield (PY) for the 
formulation 4/1 (32%) as compared with the formulation 1/4 (16%), although the difference is 
not statistically significant due to the high standard deviations. The production yield is a 
measure of the interactions that take place when both polymers contact with each other. The 
fact that, in protocol A, formulation 4/1 has a higher yield than formulation 1/4 might indicate 
that chitosan has a higher charge density. When comparing the yields of 1/4 nanoparticles 
obtained with different protocols, although protocol B apparently increases the yield, the 
differences are not significant.  
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Table 4.1: Production yield of unloaded FUC/CS nanoparticles of mass ratios 1/4 and 4/1 
obtained by different protocols (mean ± SD, n = 6). 
Protocol FUC/CS Production Yield (%) 
A 
4/1 32 ± 19 
1/4 16 ± 11 
B 1/4 26 ± 13 
 
 
1.1.1 Stability assay  
 
FUC/CS nanoparticles of mass ratios of 1/4 and 4/1 were monitored for their storage 
stability along time, concerning size and zeta potential. One of the most common problems of 
colloidal particles relies on their tendency for flocculation [24]. This is frequently 
accompanied by a decrease in zeta potential to values below 30 mV (in modulus), where the 
repulsive forces are not enough to maintain nanoparticles separated from each other, leading 
to aggregation.  
In this study, aqueous suspensions of FUC/CS nanoparticles were maintained at 4 ºC for 
a period of 170 days. Nanoparticles of formulation 4/1 registered a slight size decrease at the 
beginning, maintaining stable after that (Graphic 4.3). Nevertheless, as compared with the 
initial size (518 nm), differences were only statistically significant at the last time point (170 
days; p < 0.05), in which the registered size was 400 nm. Concerning zeta potential, apart for 
an apparent instability at the beginning, that was not significant anyway, the zeta potential 
maintained relatively stable, being -41 mV for fresh nanoparticles and -38 mV after 170 days. 
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Graphic 4.3: Evolution of () size and () zeta potential of FUC/CS = 4/1 nanoparticles 
along time (aqueous suspension stored at 4 ºC), (mean ± SD, n = 6). 
 
 
FUC/CS = 1/4 nanoparticles exhibited a very similar behavior (Graphic 4.4), with a slight 
size decrease from 435 to 331 nm in 170 days. Zeta potential also registered an initial 
variation, but the value registered at the end of 170 days (42 mV) was very similar to the 
initial (43 mV). 
In a general manner, it can be said that nanoparticles register some slight variations in 
their physicochemical characteristics upon 170 days of storage at 4 ºC, although the variations 
do not compromise the intended application as protein carriers for mucosal administration. 
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Graphic 4.4: Evolution of () Size and () zeta potential of FUC/CS= 1/4 nanoparticles 
along time (aqueous suspension stored 4 ºC), (mean ± SD, n = 3). 
 
 
4.2 Association of proteins to FUC/CS nanoparticles  
 
To choose the most suitable formulation for the encapsulation of biomolecules, key 
features were taken into account, namely concerning particle size, which drives the interaction 
with mucosal epithelia. FUC/CS nanoparticles 1/4 and 4/1 were selected to undergo protein 
encapsulation, as they display the smaller sizes and also opposite charges that might further 
affect cell interaction, which study is of interest in the field. Nanoparticles were tested 
regarding their ability to associate model proteins of different molecular weights, namely 
BSA (67 kDa), ovalbumin (44 kDa) and insulin (5.7 kDa). In addition, protein-loaded 
nanoparticles were characterised for their physicochemical properties. Because of time 
limitations, nanoparticles encapsulating BSA were the most completely studied and, 
therefore, only the results regarding these nanoparticles are displayed and discussed in the 
main document. Results regarding the physicochemical proprieties of ovalbumin- and 
insulin–loaded nanoparticles are described on appendix 5. 
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4.2.1 Encapsulation efficiency  
 
The determination of BSA encapsulation efficiency was tested for different formulations 
of FUC/CS nanoparticles, varying not only the mass ratios (1/4 and 4/1) but also the order of 
addition of the polymers (protocols A and B) and also the polymer in which BSA is mixed 
prior to nanoparticle formation. RP-HPLC was used to determine the encapsulation 
efficiency, a method that is based on the adsorption of hydrophobic molecules onto a 
hydrophobic stationary phase in a polar mobile phase. BSA has a great affinity to adsorb on 
hydrophobic surfaces [67], which can be reduced by decreasing the mobile phase polarity by 
using organic solvents (acetonitrile) resulting in desorption and elution from the reverse phase 
column. BSA desorption occurred with a gradient flow of water/acetonitrile from 95:5 to 
35:65 in 15 min, both solvents contained 0.1% of TFA ,which helped the BSA to desorb. [68]. 
BSA was eluted at around 8.5 min, and the peak shape and intensity were similar to those of 
pure BSA samples in the presence of all polymers (figure 4.2 D, E). The retention time of 
each polymer (figure 4.2 B, C) was determined and revealed to be different from BSA (figure 
4.2 A), thus not interfering with BSA determination. To identify each substance, a 
simultaneous absorbance spectrum was preformed to each peak and compared with the 
absorbance spectrums of pure BSA, fucoidan and chitosan respectively I, II and III in figure 
4.2. However, there was an overlap spectrum of the solvent acetonitrile that was overcome by 
reading BSA at 280 nm. 
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Figure 4.2: RP-HPLC runs of (A) BSA in acetic acid 1% (w/w), (B) fucoidan and (C) 
chitosan and respective spectrums I, II and III. RP-HPLC runs of (D) low encapsulation 
efficiency FUC/CS = 1/4, (E) high encapsulation efficiency FUC/CS = 4/1. 
 
 
The results in graphic 4.5 represent the encapsulation efficiency (EE) of BSA-loaded 
FUC/CS nanoparticles of mass ratios 1/4 and 4/1 prepared with protocols A and B and with 
prior BSA incorporation in different polymers solutions. FUC/CS nanoparticles effectively 
encapsulated BSA. In an initial stage of this study, BSA, insulin and ovalbumin were also 
associated to nanoparticles and the respective encapsulation efficiencies were estimated using 
the Bradford protein assay, measuring the absorbance by spectrophotometry at 595 nm 
(Tecan-Infinite M200, Switzerland). However, it was decided to not proceed with that method 
of quantification as there chitosan amino groups were interfering in the quantifications.  Data 
obtained with this methodology can be found in appendix 5. 
 Graphic 4.5 shows a rather different profile of protein association between FUC/CS 
nanoparticles 1/4 and 4/1 (p < 0.05). FUC/CS *4/1 and 4/1* from protocol A displayed, 
respectively, encapsulation efficiencies of 98% and 100%, while protocol B resulted in a 
mean of 103% for both formulations. This means that, whatever the variables, the 
encapsulation efficiency is very high and remarkable as comparing with the majority of 
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studies regarding protein encapsulation in nanoparticles. In turn, FUC/CS *1/4 and 1/4* from 
protocol A displayed, respectively, 55% and 11% encapsulation efficiency, while those 
produced with protocol B resulted in 87% and 19%, respectively. As a general trend, 
formulations with mass ratio of 4/1 exhibited better ability to encapsulate BSA as compared 
with 1/4, whatever the tested variables (p < 0.05). Additionally, for both FUC/CS mass ratios 
1/4 and 4/1 higher encapsulation efficiencies were achieved when BSA was mixed with the 
polymer with the lowest concentration in each formulation, prior to the addition into the other 
polymer solution (p < 0.05). Regarding the effect of changing the order of addition of 
polymers, a statistically significant difference was observed for formulations *1/4, 1/4* and 
*4/1 (p<0.05).  
 
 
Graphic 4.5: Graphic representation of FUC/CS nanoparticles encapsulation efficiency, with 
protocol A () and B () and prior BSA (*) incorporation in either polymeric solutions. 
(Mean ± S.D., n= 3). 
 
 
A more profound interpretation of the interactions between polymer and BSA in FUC/CS 
1/4 and 4/1 nanoparticles, might be achieved by the analyses of the pH of solutions used for 
nanoparticle assembly, which are expressed in table 4.2. With a pI of 4.7, BSA exposed 
positive charge when the final pH of its solution was lower than the pI, as happens when it 
was mixed with chitosan (around 3.3). In turn, when BSA was mixed with fucoidan, the final 
pH of the solution was 6.8 and, therefore, a negative charge is overall expressed. When the 
polymeric solutions were mixed together, the final pH of the nanoparticle suspensions were 
all lower than 4.7, meaning that BSA exposed positive charged at the end of all FUC/CS 
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nanoparticles preparations. A cross reference of this observation with the graphic 
representation of the encapsulation efficiency (Graphic 4.5), may explain higher 
encapsulation efficiency values for FUC/CS 4/1. Since these nanoparticles contain higher 
amount of fucoidan, the negatively charged polymer, and the BSA was always exposing 
opposite surface upon polymer mixture, it is quite logical to suggest that these conditions 
enhanced BSA-polymer interactions, resulting in greater encapsulations efficiencies. The 
lower EE results displayed by FUC/CS 1/4* are a result of the fact that, in this case, BSA is 
mixed at first with chitosan and, therefore, it has a positive charge in this solution. When both 
polymers are mixed, many positive charges (chitosan and BSA) are competing for the 
negatively charged groups of fucoidan, permitting only a limited interaction that results in a 
low encapsulation. If the mass ratio remains the same (FUC/CS = 1/4) but BSA is mixed with 
fucoidan and only after that there is a mixture with chitosan, there is a very significant 
increase in the encapsulation efficiency (p < 0.05), because only many positively charged 
groups of chitosan will be available to interact with the negatively charged fucoidan and BSA. 
Anyway, the resulting encapsulations are still lower than those provided by the formulation 
4/1. A statistically significant increase in the encapsulation efficiency of formulation FUC/CS 
*1/4 occurred when protocol was changed from A to B. This difference might be explained by 
the fact that adding chitosan solution into fucoidan, it was possible to maintain the pH below 
4.7 for a longer time, meaning that the protein would be exposing negative charges, thus 
promoting BSA-polymer interaction.  
 
Table 4.2: pH analyses during the FUC/CS nanoparticle production. 
Protocol FUC/CS  Solutions pH 
FUC CS BSA+ polymer (FUC/CS)+BSA 
A *1/4 6.38 3.08 6.80 3.17 
 1/4* 6.26 3.97 3.38 3.46 
 *4/1 6.28 3.22 6.71 3.48 
 4/1* 6.30 4.45 3.26 3.44 
B *1/4 6.38 3.08 6.78 3.13 
 1/4* 6.26 3.97 3.34 3.46 
 *4/1 6.28 3.22 6.79 3.48 
 4/1* 6.30 4.45 3.26 3.49 
*Polymer solution to which BSA was added prior to nanoparticle formation 
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4.2.2 Size and zeta potential 
 
 Table 4.3 presents the results corresponding to the unloaded and BSA-loaded 
nanoparticles. As can be observed, the incorporation of BSA tends to induce an increase on 
nanoparticles size, but in any case the difference is statistically significant. In turn, the zeta 
potential of nanoparticles became less negative with the incorporation of the protein in 
formulation 4/1, whatever the polymer with which BSA was mixed before nanoparticle 
assembly; while formulation 1/4 exhibits different behaviours depending on the polymer with 
which the protein is mixed before the formation of nanoparticles. The explanation for these 
different effects is probably based on different availability of charges to interact among 
polymers and the protein. To facilitate the interpretation of results Table 4.2 gathers the pH of 
used polymers, mixtures of polymers with BSA and the final nanoparticle suspension. 
 
The comparison of the zeta potentials of both FUC/CS mass ratios 4/1 and 1/4, of loaded 
and unloaded nanoparticles, shows a decrease on surface charge of nanoparticles when loaded 
with BSA, this differences were statistically significant (p<0.05). This decrease of the zeta 
potential is quite logical, and can be easily justified by the interactions polymers-protein, that 
neutralizes some of the available charges of the nanoparticles. This effect was more 
pronounced for FUC/CS=1/4 with BSA prior mix in fucoidan, when BSA was exposing 
negatively charged groups, maximizing the interaction with the available positive groups of 
chitosan. However, this great decrease on zeta potential may be caused by a rearrangement of 
nanoparticles structure, where the spatial disposition of the fucoidan chain contributes for this 
decline of the surface charge. The absence of a decrease on FUC/CS 1/4 with BSA prior mix 
in chitosan can be explained by the low encapsulation efficiency of this formulation. 
 
Table 4.3: Physicochemical characteristics of unloaded and BSA-loaded FUC/CS (1/4 and 
4/1) nanoparticles (mean ± SD, n = 3). 
 
                               *Polymer solution to which BSA was added prior to nanoparticle formation 
Protocol FUC/CS Size (nm) Zeta potential (mV) 
A 
4/1 456 ± 4 -42 ± 1 
*4/1 521 ± 55 -37 ± 3 
4/1* 525 ± 53 -33 ± 4 
B 
1/4 372 ± 5 +46 ± 2 
*1/4 415 ± 71 +19 ± 5 
1/4* 435 ± 49 +53 ± 5 
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4.2.3 Determination of BSA-loaded nanoparticles production yield and loading 
capacity 
For this study were selected for characterization the FUC/CS mass ratios 4/1 and 1/4 
from protocol A and B. As already referred in the above section of unloaded nanoparticles 
production yield, Protocol B was not trialled for 4/1 nanoparticles. Prior incorporation BSA in 
either polymeric solutions was not tested. Results of this characterization regarding insulin 
and ovalbumin can be found in appendix 5 Table 4.4 shows an increase on nanoparticle 
productions yield upon BSA incorporation, but this differences were only statistically 
significant for FUC/CS nanoparticles 4/1 and 1/4 for protocol A (p< 0.050). The most 
notorious increase on production yield was observed by FUC/CS 4/1 upon BSA 
incorporation, where nanoparticles gain about 100% of mass relatively to the unloaded 
nanoparticles. Showed in table 4.4 are also the loading capacities (LC) of FUC/CS 
nanoparticles. This characteristic represents the amount of protein relatively to the total mass 
of nanoparticles, which compose each FUC/CS formulation for example, FUC/CS 1/4 had a 
49 % LC, means that about half of this particle is compose of BSA and the other of polymer. 
Once again the enhancement of the nanoparticle BSA associations was clear in FUC/CS 1/4 
when protocol A (36 %) was replaced by B (49%). This shows that protocol B can improve 
the profitability of these processes, since although PY of FUC/CS 1/4 did not increase 
significantly when protocol change from A (30%) to B (33%), although cross reference with 
LC from both protocols (36%) A and (49 %) B shows that the particles can associate more 
protein, in fact half of the particles mass content was protein. 
 
Table 4.4: Production yield (PY) of loaded and unloaded FUC/CS 1/4 and 4/1nanoparticles 
(NP) and loading capacities, (mean ± S.D., n> 3). 
 
Protocol FUC/CS 
BSA-loaded NP 
PY (%)  LC (%) 
A 
4/1* 65 ± 15  29 ± 7 
*1/4 30 ± 7  36 ± 11 
B *1/4 33 ± 8  49 ± 11 
  *Polymer solution to which BSA was added prior to nanoparticle formation 
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5 Conclusions 
 
This work demonstrates that the developed fucoidan/chitosan (FUC/CS) nanoparticles are 
suitable to be used as protein carriers systems in the ambit of systemic mucosal 
administration. These nanoparticles are produced in complete hydrophilic conditions, by a 
very mild procedure of ionic interaction between the negatively charged fucoidan sulphate 
groups and the oppositely charged amino groups of chitosan. This procedure avoids the use of 
organic solvents and other aggressive conditions that might be detrimental for the integrity of 
the drug to be encapsulated. The macromolecules bovine albumin serum (BSA), insulin and 
ovalbumin, used in this study as model proteins, were efficiently associated to the developed 
drug delivery systems, as demonstrated by the physicochemical characterization of the 
systems. The optimization of several variables of the nanoparticle production method allowed 
obtaining very high encapsulation efficiencies. The small sizes and high negative and positive 
charges displayed by the developed nanoparticles are considered to hold potential for an 
application in mucosal delivery of macromolecules. Additionally, FUC/CS nanoparticles 
demonstrated to be relatively stable in aqueous suspension, only registering some slight 
variations in their physicochemical characteristics upon 170 days of storage at 4 ºC, although 
these do not compromise the intended application as protein carriers for mucosal 
administration. In order to establish a complete characterization of the developed 
nanoparticulate systems, FUC/CS nanoparticles must undergo further studies, namely the 
determination of release profile and the toxicity assessment, both in vitro and in vivo. 
. 
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7 Appendix 
7.1 Appendix 1 
 DEVELOPMENT OF FUCOIDAN/CHITOSANNANOPARTICULATE SYSTEMS FOR 
PROTEIN ADMINISTRATION THROUGH MUCOSAL ROUTES 
 
Sara Ferreira*, Ana Grenha 
 
CBME - Centre for Molecular and Structural Biomedicine / IBB - Institute for 
Biotechnology and Bioengineering, University of Algarve, Portugal; 
*sara_atayde@hotmail.com 
 
INTRODUCTION 
Protein-based biomacromolecules have been 
used for long in pharmacological therapy, but 
their administration through non-parenteral 
routes is a difficult task, due to stability issues 
mainly attributed to pH and enzymatic 
contents in mucosal surfaces. It has been a 
consensus that mucosal routes are valuable 
alternatives for drug administration, but this 
demands the development of adequate 
carriers that confer stability and protection 
against the mentioned aggressive 
environments (1). Nanoparticulate systems 
have proven promising for this end, owing to 
their high surface-to-volume ratio and capacity 
for drug encapsulation (2). Using natural 
polymers for nanocarriers production is 
advantageous due to the requirements of 
biocompatibility, biodegradability and absence 
of toxicity, which are mandatory in any 
biomedical application. Fucoidan and chitosan 
are two of these natural polymers, respectively 
extracted from brown seaweed (Fucus 
vesiculosus) with 95% of fucose sulfated 
esters (anionic polysaccharide) (3), and the 
exoskeleton of crustaceans. In the case of 
chitosan a further step of partial deacetylation 
of chitin is necessary to obtain the cationic 
polysaccharide (4). In this work, 
fucoidan/chitosan (FUC/CS) nanoparticles 
were prepared by polyelectrolyte complexation 
(5). The obtained nanocarriers were optimized 
in terms of several variables, being evaluated 
for their capacity to associate proteins. 
 
MATERIAL AND METHODS 
Preparation of FUC/CS nanoparticles: 
Nanoparticles were prepared by a method of 
polyelectrolyte complexation (6). Briefly, CS 
was dissolved in acetic acid 1% (w/w) and 
FUC was dissolved in purified water. FUC/CS 
nanoparticles were spontaneously formed at 
room temperature upon incorporation of FUC 
solution into CS solution (FUC/CS mass ratios 
between 4/1 and 1/4) and vice-versa. Different 
mass ratios and the order of addition of 
polymeric solutions were studied as variables. 
Protocol A consisted in the addition of FUC 
over CS and Protocol B was the opposite. 
Nanoparticles were isolated by centrifugation 
(16000 x g, 30 min, 15 ºC) and resuspended in 
100 µL of milli-Q water.  
Model biomacromolecules (BioM) were 
associated to the nanoparticles, including 
bovine serum albumin (BSA), ovalbumin and 
insulin. Proteins were dissolved in appropriate 
solvents (water or sodium hydroxide 0.1 M) 
and added to either CS or FUC solution, in 
order to provide the protein with opposite 
charge in comparison with the polymer 
presented at the highest concentration in each 
formulation. The solution of the second 
polymer is then poured into the previously 
prepared polymer/protein solution to produce 
the nanoparticles. 
Nanoparticles characterization: 
Nanoparticles production yield was calculated 
by gravimetry, comparing the real weight of 
nanoparticles with the initial amount of solids 
used for their production (n = 3). Nanocarriers’ 
size and zeta potential were measured by 
photon correlation spectroscopy and laser 
Doppler anemometry, respectively (Zetasizer
®
 
Nano ZS, Malvern Instruments) (n = 3). 
Nanoparticles supernatant was assessed to 
determine the amount of free BioM using the 
Bradford protein assay and measuring the 
absorbances by spectrophotometry at 595 nm 
(Tecan-Infinite M200, Switzerland). A 
calibration curve was made using the 
supernatant of blank nanoparticles. BioM 
encapsulation efficiency (E.E.) and loading 
capacity (L.C.) were calculated comparing the 
non-associated protein present in the 
supernatant with the total amount added for 
nanoparticles production, as follows: 
 
E. E.  % =  
Total BSA  Free BSA
Total BSA
 × 100 
 
.E. (%) 
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L. C.  % =  
Total BSA  Free BSA
Nanoparticle weight
 × 100
 
 
Evaluation of nanoparticles stability:  
A study of the nanoparticles (FUC/CS = 4/1 
and 1/4) stability in water was performed at 4 
ºC. Unloaded nanoparticles were isolated by 
centrifugation and resuspended in water 
afterwards. Sizes were monitored during 22 
days, using the above mentioned techniques 
(n = 3). 
 
RESULTS AND DISCUSSION 
Nanoparticles characterization: 
The two variables studied in the production 
of FUC/CS nanoparticles, which consist in 
polymer concentration (CS and FUC) and the 
order of addition of polymeric solutions, 
resulted in remarkable effects over 
nanoparticles characteristics. Sizes ranged 
between 300 and 700 nm (Figure 1) and the 
highest size corresponded to the highest 
amount of materials composing the 
nanoparticles (FUC/CS = 1/1). Moreover, a 
complete shift of zeta potentials was 
observed, varying from -42 to +49 mV 
(Figure 2), which reflects the highest amount 
of negative or positive polymer composing 
the nanoparticles. 
 
Figure 1 - FUC/CS nanoparticles size 
corresponding to different mass ratios and 
preparation protocols (mean ± SD, n = 3). 
 
 
Figure 2 – FUC/CS nanoparticles zeta 
potential obtained for different mass ratios 
and preparation protocols (mean ± SD, n = 3).  
 
The most remarkable effect of protocol 
changes is related with BSA encapsulation. 
In the formulation FUC/CS 1/4, changing 
preparation protocol from A to B, it is 
observed a 60-70% increase in the 
encapsulation efficiency (from 11-20% in 
protocol A to 83-85% in protocol B). 
Formulation 4/1 also shows high BSA 
encapsulation efficiency, up to 88% with 
protocol A. Assays regarding ovalbumin and 
insulin encapsulation show efficiency of 51% 
and 91%, respectively, in formulation 
FUC/CS = 4/1 comparatively to the lower 
efficiency (14%) for both proteins in 1/4 
FUC/CS formulation. Release assays are 
presently being performed. 
 
Evaluation of nanoparticles stability:  
The stability assay revealed that, when 
stored at 4ºC, the nanoparticles (FUC/CS = 
1/4 and 4/1) size remains stable for at least 
22 days, for formulations obtained by both 
protocols A and B. Further studies are being 
performed to assess longer time periods. 
 
 
CONCLUSIONS 
Considering the physicochemical properties, 
the ability to associate proteins and the 
demonstrated stability, FUC/CS 
nanoparticles are considered good 
candidates for drug delivery purposes. The 
results indicate that the use of protocol A and 
B in 4/1 and 1/4 FUC/CS formulations, 
respectively, provide high BSA encapsulation 
efficiency.  
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7.2 Appendix 2 
 
 
 
FUCOIDAN/CHITOSAN NANOPARTICLES AS PROTEIN  CARRIERS 
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Bioengineering, University of Algarve, Faro, Portugal. 
 
 
KEYWORDS 
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INTRODUCTION 
 
Fucoidan and chitosan are natural polymers, respectively extracted from brown seaweed (Fucus vesiculosus) and 
containing 95% of fucose sulfated esters (anionic polysaccharide) [1], and from the exoskeleton of crustaceans. 
Displaying opposite charges, these polysaccharides enable the production of nanoparticles by polyelectrolyte 
complexation, occurring under very mild conditions [2]. Nanoparticles have proven to be promising vehicles in 
protein delivery, due to their high surface-to-volume ratio and capacity for association of macromolecules. In this 
work, fucoidan/chitosan (FUC/CS) nanoparticles of various mass ratios (1/4 to 4/1, w/w) were prepared by means 
of an electrostatic interaction, displaying different size and zeta potential. Several conditions were explored to 
maximise protein incorporation, either varying 1) the order of addition of polymeric solutions (Protocol A: FUC 
into CS, or Protocol B: CS into FUC), or 2) the polymeric solution (FUC or CS) to which the protein is added 
prior to nanoparticle formation. Bovine serum albumin (BSA), ovalbumin and insulin were used as model 
proteins. The use of natural polymers is expected to provide the basis for biocompatibility and absence of 
toxicity, which are mandatory in any biomedical application [3]. Importantly, the application of fucoidan in the 
preparation of nanoparticles for drug delivery purposes was never reported before. 
 
 
RESULTS & DISCUSSION 
 
FUC/CS nanoparticles display sizes of 300 - 700 nm and zeta potential from -42 to +49 mV. In approach 1), BSA 
was used as model protein, being always incorporated in FUC solution prior to nanoparticle formation. Higher 
encapsulation efficiencies were obtained for formulations FUC/CS = 4/1 produced according to protocol A (88%) 
and FUC/CS = 1/4 prepared by protocol B (85%). The approach 2) was tested for BSA, insulin and ovalbumin, 
and protocols A and B were used for formulations 4/1 and 1/4, respectively. Higher encapsulation efficiency is 
always observed when the protein is mixed with in the solution of the polymer present in the lower ratio in the 
final formulation. Release assays are presently being performed. The performed experiments demonstrate the 
importance of controlling the protein charge in the moment of providing the interaction with polymers. The size 
and zeta potential of FUC/CS nanoparticles (1/4 and 4/1, w/w) remain stable for up to 6 months, upon storage at 4 
ºC. Considering the physicochemical properties and stability, as well as the ability to associate different proteins, 
FUC/CS nanoparticles are deemed suitable for drug delivery purposes. 
National funding from Portuguese Foundation for Science and Technology (project PTDC/SAU-
FCF/100291/2008 and PEst-OE/EQB/LA0023/2011) is acknowledged. 
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7.3 Appendix 3 
 
The conditions on which nanoparticles formed were optimized. Temperature reveled to 
have great influence on the nanoparticles formation. During this study nanoparticles were 
formed at room temperature oscillating between 17-22 ºC, agglomerates were formed above 
or under this temperature range (data not shown). The Drop wise incorporation of the 
polymers revealed as a crucial step for nanoparticles formation. A small increase in the rate of 
addition of polymers causes major changes in terms of size (data not shown). To outcome this 
problems with nanoparticle resuspension was adopted a strategy that consisted on finding the 
accurate amount of glycerol for each formulation, by phased additions of more 10 µL glycerol 
in nanoparticles isolation procedure. The results of this optimization were illustrated in 
graphic 1. The graphic 7.1 shows the accurate amount of glycerol for FUC/ CS mass ratio 
formulation 1/1, 2/1, 3/1, 4/1 and 5/1 were 20, 50, 20, 10 and 10 µL respectively. The excess 
of glycerol usually contributes to nanoparticle aggregation.  
 
 
Graphic 7.1: Glycerol optimization for each formulation 
. 
The conditions adopted for the nanoparticle isolation procedure, were centrifuge velocity 
of 16000 G, at 15ºC during 30 minutes that correspond to a standardization used by the 
research group.  
  
Nanoparticles 
Clusters 
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7.4 Appendix 4 
 
FUC/CS nanoparticles size and zeta potential, from protocol A (table 7.1) and B (table 
7.2). 
 
Table 7.1: FUC/CS nanoparticles size and zeta potential, from protocol A (Mean± SD, n = 3). 
FUC\CS 
(w/w) 
Size 
(nm) 
Zeta potential  
(mV) 
 
4\1 456±4 -42±1 
3\1 547±21 -40±1 
2\1 510±27 -41±5 
1\1 564±21 49±4 
1\2 544±10 45±12 
1\3 531±3 49±6 
1\4 366±41 46±6 
 
 
Table 77.2: FUC/CS nanoparticles size and zeta potential, from protocol (Mean± SD, n=3) 
FUC\CS 
(w/w) 
Size 
(nm) 
Zeta potential 
 (mV) 
 
4\1 338±44 -37±11 
3\1 417±47 -42±1 
2\1 420±28 -37±3 
1\1 676±34 43±12 
1\2 591±58 45±4 
1\3 435±33 40±1 
1\4 372±5 46±2 
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7.5 Appendix 5 
7.5.1 Proteins association of FUC/CS nanoparticles 
 BSA, ovalbumin and insulin were dissolved in appropriate solvents respectively in water 
and sodium hydroxide 0.1 M, and then added to either CS or FUC solution, in order to 
provide the protein with opposite charge in comparison with the polymer presented at the 
highest concentration in each formulation. Nanocarriers’ size and zeta potential were 
measured by photon correlation spectroscopy and laser Doppler anemometry, respectively 
(Zetasizer
®
 Nano ZS, Malvern Instruments) (n = 3).Table x contains size and zeta potential of 
insulin and ovalbumin –loaded nanoparticles. The graphic 7.2 representation of the tabled size 
values, plus BSA-loaded and unloaded nanoparticles, reveals the specificity of the 
interactions between these polymers and each protein, whereas displays different behaviors in 
terms of sizes. 
 
 
Graphic 7.2: Representation of FUC/CS mass ratios 1/4 and 4/1 sizes, of unloaded (), 
insulin (), ovalbumin () and BSA () -loaded nanoparticles (Mean ± S.D, n=3). 
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Nanoparticles production yield (table 7.3) was calculated by gravimetry, comparing the 
real weight of nanoparticles with the initial amount of solids used for their production (n = 3). 
  
Table 7.3: Production yield and loading capacity of insulin and ovalbumin -loaded 
nanoparticles of FUC/CS mass ratio 1/4 and 4/1(Mean ± SD, n>3). 
Protocol 
FUC/CS 
(w/w) 
Insulin-loaded NP 
Ovalbumin-loaded 
NP 
P.Y. 
(%) 
 
L.C. 
(%) 
 
P.Y. (%) 
 
L.C. 
(%) 
 
A 
*4/1 - - 40±9 21±6 
4/1* 45±13 37±11 46±8 27±5 
B 
*1/4 33±14 13±6 16±5 13±5 
1/4* - - 24±11 0 
                     *Polymer solution to which BSA was added prior to nanoparticle formation 
 
 
Nanoparticles supernatant was assessed to determine the amount of free BioM using the 
Bradford protein assay and measuring the absorbance by spectrophotometry at 595 nm 
(Tecan-Infinite M200, Switzerland). A calibration curve was made using the supernatant of 
blank nanoparticles. BioM encapsulation efficiency (EE) and loading capacity (LC) were 
calculated comparing the non-associated protein present in the supernatant with the total 
amount added for nanoparticles production, as described in Materials and Methods. 
These assays with ovalbumin and insulin happened in an early stage of this work, where 
some characteristic of the polymer were not completely described. An example of this was the 
fact that using Bradford assay to measure the proteins encapsulations efficiency, not only the 
proteins were being quantify, but also fucoidan, jeopardizing the results. With this work was 
evident that each protein has is one unique interaction with this polymers combination. In 
graphic 7.3 represents the different encapsulation efficiencies for the 3 model proteins used in 
this study, for nanoparticles FUC/CS 1/4 and 4/1 mass ratios. The most remarkable effect 
occurs during BSA encapsulation when protocol changes from A to B in FUC/CS 1/4 
formulation were observed an increase in 70-80 % the encapsulation ability (EE of 88 %). 
Still regarding BSA, the 4/1 formulation shows as well a great encapsulation ability (EE of 
81-88 %) with protocol A. In ovalbumin and insulin encapsulation, the FUC/CS mass ratio 
4/1 had the highest encapsulation efficiencies respectively 51% and 91% that contrast with 
the very low encapsulation efficiencies in FUC/CS mass ratio 1/4 of 14% for both proteins.  
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Graphic 7.3: Encapsulation efficiency of FUC/CS nanoparticles 1/4 from protocol A () 
and B () and 4/1 for protocol A (). (Mean ± S.D., n >3) 
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